Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Schalper, K.A. (Kurt A.), Rodriguez-Ruiz, M.E. (María Esperanza), Diez-Valle, R. (Ricardo), López-Janeiro, Á. (Álvaro), Porciuncula, A. (Angelo), Idoate, M.A. (Miguel Ángel), Inoges, S. (Susana), Andrea, C.E. (Carlos Eduardo) de, Lopez-Diaz-de-Cerio, A. (Ascensión), Tejada-Solis, S. (Sonia), Berraondo, P. (Pedro), Villarroel-Espindola, F. (Franz), Choi, J. (Jungmin), Gurpide, A. (Alfonso), Giraldez, M. (Miriam), Goicoechea, I. (Iosune), Gallego-Perez-Larraya, J. (Jaime), Fernandez-Sanmamed, M. (Miguel), Perez-Gracia, J.L. (Jose Luis), Melero, I. (Ignacio)
Formatua: info:eu-repo/semantics/article
Hizkuntza:eng
Argitaratua: Nature Publishing Group 2024
Gaiak:
Materias Investigacion::Ciencias de la Salud::Oncología
Glioblastoma
Neoadjuvant nivolumab
Sarrera elektronikoa:https://hdl.handle.net/10171/68722

Internet

https://hdl.handle.net/10171/68722

Antzeko izenburuak